CMS Should Account For Cost Of Blood Products, MedPAC Recommends
This article was originally published in The Gray Sheet
Executive Summary
The Centers for Medicare & Medicaid Services should account for the cost of blood products when it next revises the hospital market basket index, the Medicare Payment Advisory Commission concluded at its Nov. 15 meeting in Washington, D.C
You may also be interested in...
AdvaMed To MedPAC: Does CMS Properly Reimburse Hospitals For Blood?
Medicare's annual 2.8% increase in the inpatient hospital input price index from 1996 to 2000 was not sufficient to keep pace with the 7% annual increase in costs of producing blood, AdvaMed Associate VP for Payment and Policy Stephen Hull testified Oct. 19 at a Medicare Payment Advisory Commission (MedPAC) meeting in Washington, D.C.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.